250 related articles for article (PubMed ID: 11497353)
1. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
Orr RM
Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
[TBL] [Abstract][Full Text] [Related]
2. Fomivirsen approved for CMV retinitis.
Roehr B
J Int Assoc Physicians AIDS Care; 1998 Oct; 4(10):14-6. PubMed ID: 11365956
[TBL] [Abstract][Full Text] [Related]
3. Fomivirsen approved for CMV retinitis: first antisense drug.
AIDS Treat News; 1998 Sep; (302):7. PubMed ID: 11365764
[TBL] [Abstract][Full Text] [Related]
4. New CMV retinitis drug approved.
Body Posit; 1998 Oct; 11(10):10. PubMed ID: 11365907
[TBL] [Abstract][Full Text] [Related]
5. New CMV drug won't replace other therapies.
AIDS Alert; 1998 Nov; 13(11):124-6. PubMed ID: 11365968
[TBL] [Abstract][Full Text] [Related]
6. Advances in CMV management: fomivirsen (Vitravene) approved.
Proj Inf Perspect; 1998 Dec; (26):7. PubMed ID: 11366499
[TBL] [Abstract][Full Text] [Related]
7. Fomivirsen.
Highleyman L
BETA; 1998 Apr; ():29, 31. PubMed ID: 11365261
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
9. Fomivirsen.
Perry CM; Balfour JA
Drugs; 1999 Mar; 57(3):375-80; discussion 381. PubMed ID: 10193689
[TBL] [Abstract][Full Text] [Related]
10. FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Highleyman L
BETA; 1998 Oct; ():5. PubMed ID: 11365993
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS.
Vitravene Study Group
Am J Ophthalmol; 2002 Apr; 133(4):467-74. PubMed ID: 11931780
[TBL] [Abstract][Full Text] [Related]
12. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
Detrick B; Nagineni CN; Grillone LR; Anderson KP; Henry SP; Hooks JJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):163-9. PubMed ID: 11133862
[TBL] [Abstract][Full Text] [Related]
14. Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.
Stone TW; Jaffe GJ
Am J Ophthalmol; 2000 Aug; 130(2):242-3. PubMed ID: 11004306
[TBL] [Abstract][Full Text] [Related]
15. First oligonucleotide in U.S. clinical trials for CMV retinitis.
AIDS Patient Care STDS; 1997 Jun; 11(3):198-9. PubMed ID: 11361805
[No Abstract] [Full Text] [Related]
16. Fomivirsen approved.
AIDS Patient Care STDS; 1998 Dec; 12(12):943. PubMed ID: 11362071
[No Abstract] [Full Text] [Related]
17. Isis presents data on safety and effectiveness of antisense CMV retinitis compound.
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50. PubMed ID: 11363533
[TBL] [Abstract][Full Text] [Related]
18. Fomivirsen for the treatment of cytomegalovirus retinitis.
Jabs DA; Griffiths PD
Am J Ophthalmol; 2002 Apr; 133(4):552-6. PubMed ID: 11931791
[No Abstract] [Full Text] [Related]
19. Anti-CMV drug trials back on-line.
GMHC Treat Issues; 1996 May; 10(5):9. PubMed ID: 11363587
[TBL] [Abstract][Full Text] [Related]
20. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
